- Question
- Does tricuspid transcatheter edge-to-edge repair (T-TEER) added to optimal medical therapy improve clinical outcomes compared with medical therapy alone in patients with severe symptomatic tricuspid regurgitation?
- Design
- Investigator-initiated, prospective, 1:1 randomized trial, unmasked per the registry, enrolling 300 patients at 24 centers in France and Belgium (March 2021 to March 2023; latest follow-up April 2024).
- Population
- Adults with severe, symptomatic, predominantly isolated tricuspid regurgitation; mean age 78 years and 63.7% women.
- Intervention
- T-TEER (clip for the tricuspid valve) plus guideline-directed optimal medical therapy (152 patients).
- Control
- Optimal medical therapy alone (148 patients).
- Primary outcome
- A composite clinical end point at 1 year combining change in NYHA class, change in patient global assessment, and occurrence of major cardiovascular events (Packer clinical composite score).
- Results
- At 1 year, the primary composite improved in 74.1% of patients with T-TEER vs 40.6% with medical therapy alone. Massive or torrential tricuspid regurgitation persisted in 6.8% vs 53.5% (P < .001). Mean KCCQ score was 69.9 vs 55.4 (P < .001), and the win ratio for the composite secondary outcome was 2.06 (95% CI, 1.38-3.08; P < .001).
- Conclusion
- T-TEER reduced tricuspid regurgitation severity and improved a composite score driven mainly by patient-reported outcomes.
- Why it matters
- It supported T-TEER as an option to relieve symptoms and improve quality of life in selected patients with severe tricuspid regurgitation, although the benefit was driven mainly by patient-reported measures and the trial was unmasked.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 18, 2026